WHO WE ARE
We promote translational oncological research in Spain.
We raise funds and finance research on all types of cancer.
We invest in tangible projects that directly benefit the patient.
We support young research talent in the field of oncology.
We have the endorsement of an external multidisciplinary team of experts.
MISSION AND VISION
The vision of the FERO Foundation is a future without cancer, a future where cancer is not a cause to death. To move closer to a cure for cancer and expedite advancements in patient outcomes, our mission is to promote translational oncological research in Spain.
WHAT TRANSLATIONAL
ONCOLOGICAL RESEARCH IS
Our raison d'être is to study the biology of cancer to better understand the disease, and thus contribute to providing improved diagnoses and treatments for patients.
Their work and commitment are essential in fundraising, as well as identifying and financing pioneering translational research projects in Spain. In collaboration with top research centers, the team also manages funded projects to ensure their proper development.
BOARD OF TRUSTEES
The Board of Trustees of the FERO Foundation is composed of fifteen individuals from the scientific, business, and cultural fields, aware of the impact of cancer on our society, sensitive to the Foundation’s mission, and convinced of the need to increase resources for oncological research.
This Board is responsible for overseeing and governing the FERO Foundation, ensuring that its foundational objectives are met and that it follows an evolutionary course. Their work and involvement facilitate the smooth functioning of the institution providing with trust to both members and collaborators.
Presidents
Silvia Garriga Sels, Degree in Economics and MBA at ESADE.
Vice Presidents
Sol Daurella Comadrán, Degree in Business Administration and MBA in Business Administration from ESADE. President of COCA-COLA EUROPACIFIC PARTNERS, PLC.
Àngels Miquel Vilanova, Degree in Fine Arts (University of Barcelona), PhD in Humanities (University of Girona), General Management Program (IESE Business School), Managing Director of Invermik 1925 SL.
Patrons
Lali Baselga Torres, Doctor in Medicine and Surgery. Head of the dermatology service at the Hospital Sant Joan de Deu in Barcelona.
Xavier Botet Campderrós, Degree in Architecture. Founder of LAOS arquitectura.
José Creuheras Margenat, Graduate in Law and Chairman of Grupo Planeta and Atresmedia.
Eusebio Díaz-Morera Puig-Sureda, Degree in Economics, MBA from IESE. Vice President of EDM.
Maria Macaya López-Mancisidor, BA in Art History and International Relations from Tufts University. President and CEO of Radika.
Marian Puig Guasch, Degree in Chemical Engineering, MBA from the Business School of Lausanne. President of ISDIN.
Mireia Tomàs Carulla, Degree in Business Administration and Management from ESADE.
Juan Pablo Tornos Mas, (Founding Trustee and Secretary), Law Degree from the UB, Managing Partner of Juan Pablo Tornos & Asociados.
Carmen Valle Mingorance, Degree in Business Administration from the University of Vic. Vice President of the Board and Executive Director of PYNCAR.
Former members of the Board of Trustees
Fernando Aleu Roda †
Luis Cantarell Rocamora
M. Ángels Campderrós Salvans
Josep Esteve Soler †
Marisa Falcó Couchoud, Condesa de Godó
Curra Orozco Serrano
Marian Puig Planas †
María Reig Moles
Leopoldo Rodés Castané †
Gonzalo Rodés Vilà
Macarena Sainz de Vicuña Primo de Rivera
Artur Suqué Puig †
OUR COMMITMMENTWITH TRANSPARENCY
Annual summary FERO activity
FERO Annual Financial Statements
Where doyou come from?
FERO arises from the concern of our founder, the oncologist Josep Baselga. A world leader in oncology, advocate for translational research, and promoter of the idea that the only path to curing cancer is through research.
In his discourse, he conveyed the idea that in the next decade, we would find the cure for cancer and spoke about the importance of collaboration to achieve it. For this reason, FERO aims to involve the entire society in the cause and support cancer researchers in Spain. Today, his words inspire a large scientific community and are an unequivocal hope for patients.
If 20 years ago only 30% of diagnosed patients survived the disease, and today we are able to cure nearly 65% of tumours, it is thanks to believing in research.
If 20 years ago only 30% of diagnosed patients survived the disease, and today we are able to cure nearly 65% of tumours, it is thanks to believing in research.
Where are we heading?
In Spain, funding for cancer research is scarce. Therefore, we want to involve the entire society in this task, which belongs to everyone, and provide the Spanish scientific community with the necessary resources to reach the end of cancer as soon as possible. Learn about the ongoing projects and programs.